RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Apple Turns 50: From Garage Startup to AI Crossroads 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Britain Courts Anthropic Amid US Defense Department Dispute 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
WINTER HAVEN, Fla., Dec. 02, 2016 -- 3B Medical, Inc. announces that an Administrative Law Judge of the United States International Trade Commission has issued an Initial Determination that ResMed (RMD) failed to satisfy the domestic industry requirement for patents relating to its CPAP masks and nasal pillow products, manufactured in Australia, Singapore and Malaysia. Gary Hnath of Mayer Brown, counsel for 3B/BMC, successfully argued that ResMed did not demonstrate sufficient U.S. content to obtain protection under Section 337 because “ResMed has not demonstrated that the value added by the alleged activities in the U.S. is significant compared to the overall manufacturing cost".
As a result of the decision, the ALJ found no violation of any of the asserted mask patents by 3B/BMC, resulting in a total victory for 3B/BMC in the ITC’s investigation. ResMed previously abandoned its appeal of the ITC’s finding that ResMed’s patent on its CPAP humidifier was invalid.
About 3B:
3B Medical is a leader in the development, marketing and distribution of medical products for the treatment of sleep disordered breathing and oxygen therapy.
Contacts: For News Media Rebecca Velazquez 3B Medical, Inc. 799 Overlook Drive Winter Haven, FL 33884 Email: [email protected] Tel: (863) 226-6285 ext. 108
